Companies in #Head and Neck Squamous Cell Carcinoma (HNSCC)

Immutep Limited is a globally operating clinical-stage biotechnology company developing novel LAG-3 (Lymphocyte Activation Gene-3) immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, with major operational and clinical research facilities in Châtenay-Malabry (Paris), France, and Berlin, Germany, the company was built around the foundational LAG-3 discoveries of CSO Dr. Frédéric Triebel. Its lead oncology asset, eftilagimod alfa (efti), is a first-in-class soluble LAG-3 fusion protein acting as an antigen-presenting cell activator targeting MHC Class II, evaluated in combination with checkpoint inhibitors across solid tumors. Following an independent data monitoring committee futility finding for the registrational Phase 3 TACTI-004 trial in 1L non-small cell lung cancer in 2026, Immutep initiated targeted workforce downsizing and trial wind-down to preserve capital and extend its cash runway into 2028 while advancing IMP761, a first-in-class LAG-3 agonist antibody in Phase 1 trials for autoimmune diseases.